Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Brian Stuglik sold 8,100 shares of Puma Biotechnology stock in a transaction on Friday, June 12th. The stock was sold at an average price of $7.20, for a total transaction of $58,320.00. Following the sale, the director owned 113,858 shares of the company's stock, valued at $819,777.60. The trade was a 6.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Puma Biotechnology Price Performance
NASDAQ PBYI opened at $7.07 on Tuesday. The company has a market cap of $359.86 million, a price-to-earnings ratio of 14.73 and a beta of 1.21. The stock's fifty day moving average price is $7.23 and its 200 day moving average price is $6.57. Puma Biotechnology, Inc. has a 1 year low of $3.03 and a 1 year high of $7.90.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.09. The company had revenue of $44.81 million during the quarter, compared to analysts' expectations of $42.00 million. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%. Research analysts expect that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on PBYI shares. Weiss Ratings downgraded Puma Biotechnology from a "hold (c+)" rating to a "hold (c)" rating in a report on Monday, May 11th. Wall Street Zen lowered shares of Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has a consensus rating of "Hold".
View Our Latest Stock Analysis on Puma Biotechnology
Institutional Investors Weigh In On Puma Biotechnology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its stake in shares of Puma Biotechnology by 4,823,365.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company's stock valued at $5,123,000 after buying an additional 964,673 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Puma Biotechnology by 238.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 793,962 shares of the biopharmaceutical company's stock valued at $4,724,000 after buying an additional 559,345 shares during the period. AQR Capital Management LLC boosted its stake in shares of Puma Biotechnology by 410.1% in the fourth quarter. AQR Capital Management LLC now owns 666,605 shares of the biopharmaceutical company's stock worth $3,966,000 after buying an additional 535,933 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of Puma Biotechnology by 78.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 773,485 shares of the biopharmaceutical company's stock worth $4,602,000 after buying an additional 339,924 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its holdings in Puma Biotechnology by 35.3% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company's stock worth $6,666,000 after acquiring an additional 292,108 shares during the period. 61.29% of the stock is owned by institutional investors and hedge funds.
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.
The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
